INCY vs HALO

For growth investors, Halozyme Therapeutics, Inc.

(HALO) is the stronger pick with 37. 6% revenue growth year-over-year, versus 21. 2% for Incyte Corporation (INCY). Incyte Corporation (INCY) offers the better valuation at 15. 6x trailing P/E (13. 3x forward), making it the more compelling value choice. Analysts rate Incyte Corporation (INCY) a "Buy" — based on 44 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Incyte Corporation (INCY) is the cheapest at 15.

6x versus Halozyme Therapeutics, Inc. at 25. 9x. On forward P/E, Halozyme Therapeutics, Inc. is actually cheaper at 8. 2x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Halozyme Therapeutics, Inc.

(HALO) delivered a total return of +39. 1%, compared to +21. 3% for Incyte Corporation (INCY). Over 10 years, the gap is even starker: HALO returned +598. 4% versus INCY's +41. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Halozyme Therapeutics, Inc.

(HALO) is the lower-risk stock at 0. 56β versus Incyte Corporation's 0. 87β — meaning INCY is approximately 57% more volatile than HALO relative to the S&P 500.

By revenue growth (latest reported year), Halozyme Therapeutics, Inc.

(HALO) is pulling ahead at 37. 6% versus 21. 2% for Incyte Corporation (INCY). On earnings-per-share growth, the picture is similar: Incyte Corporation grew EPS 41. 7% year-over-year, compared to -25. 4% for Halozyme Therapeutics, Inc.. Over a 3-year CAGR, HALO leads at 28. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Incyte Corporation (INCY) is the more profitable company, earning 25.

0% net margin versus 22. 7% for Halozyme Therapeutics, Inc. — meaning it keeps 25. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus 26. 1% for INCY. At the gross margin level — before operating expenses — INCY leads at 91. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Halozyme Therapeutics, Inc.

(HALO) trades at 8. 2x forward P/E versus 13. 3x for Incyte Corporation — 5. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HALO: 18. 1% to $78. 33.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Halozyme Therapeutics, Inc.

(HALO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 56), +598. 4% 10Y return). Both have compounded well over 10 years (HALO: +598. 4%, INCY: +41. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.